Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1178-1183

  Cibeira, María Teresa ^a   Fernández de Larrea, Carlos ^a   Navarro, Alfons ^a   Díaz, Tania ^a   Fuster, Dolors ^a   Tovar, Natalia ^a   Rosiñol, Laura ^a   Monzó, Mariano ^a   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

DNA repair; Myeloma; Response; SNP; Survival; Thalidomide

Indexed keywords

ADENINE; CELL NUCLEUS RECEPTOR; CYTOSINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 5; GLUTATHIONE TRANSFERASE T1; INTERLEUKIN 6; NUCLEAR PROTEIN; NUCLEAR RECEPTOR NR1I2; SULFOTRANSFERASE; SULFOTRANSFERASE 1C2; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC5 PROTEIN;

ABCB1 GENE; ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; DNA REPAIR; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; ERCC1 GENE; ERCC2 GENE; ERCC5 GENE; EVENING DOSAGE; FEMALE; GASTROINTESTINAL DISEASE; GENE; GSTT1 GENE; HEART DISEASE; HETEROZYGOSITY; HUMAN; INFECTION; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NR1I2 GENE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SULT1C2 GENE; TOP2A GENE; VEGFA GENE; XPA GENE; XRCC1 GENE; XRCC5 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80051470435     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.009     Document Type: Article

References (41)

1. Palumbo A., Facon T., Sonneveld P., Bladé J., Offidani M., Gay F., et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008, 111:3968-3977.
2. Bladé J., Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008, 20:697-704.
3. Bladé J., Esteve J., Rosiñol L., Perales M., Montoto S., Tuset M., et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001, 28:588-592.
4. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
5. Cibeira M.T., Rozman M., Segarra M., Lozano E., Rosiñol L., Cid M.C., et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008, 41:244-253.
6. Monzó M., Navarro A., Ferrer G., Artells R. Pharmacogenomics: a tool for improving cancer chemotherapy. Clin Transl Oncol 2008, 10:628-637.
7. Bladé J., Samson D., Reece D., Apperley J., Björkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
8. Monzó M., Brunet S., Urbano-Ispizua A., Navarro A., Perea G., Esteve J., et al. CETLAM. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006, 107:4871-4879.
9. Dumontet C., Landi S., Reiman T., Perry T., Plesa A., Bellini I., et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 2010, 45:1316-1324.
10. Vacca A., Scavelli C., Montefusco V., Di Pietro G., Neri A., Mattioli M., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005, 23:5334-5346.
11. Teo S.K., Colburn W.A., Tracewell W.G., Kook K.A., Stirling D.I., Jaworsky M.S., et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004, 43:311-327.
12. Ando Y., Price D.K., Dahut W.L., Cox M.C., Reed E., Figg W.D. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 2002, 1:669-673.
13. Li Y., Hou J., Jiang H., Wang D., Fu W., Yuan Z., et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 2007, 92:1246-1249.
14. Mileshkin L., Stark R., Day B., Seymour J.F., Zeldis J.B., Prince H.M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006, 24:4507-4514.
15. Vangsted A.J., Søeby K., Klausen T.W., Abildgaard N., Andersen N.F., Gimsing P., et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer 2010, 10:404.
16. Johnson D.C., Corthals S., Ramos C., Hoering A., Cocks K., Dickens N.J., et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008, 112:4924-4934.
17. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492-494.
18. Cibeira M.T., Rosiñol L., Ramiro L., Esteve J., Torrebadell M., Bladé J. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 2006, 77:486-492.
19. Rosiñol L., Cibeira M.T., Bladé J., Esteve J., Aymerich M., Rozman M., et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004, 89:832-836.
20. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295.
21. Thacker J., Zdzienicka M.Z. The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair 2004, 3:1081-1090.
22. Monzo M., Moreno I., Navarro A., Ibeas R., Artells R., Gel B., et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007, 72:364-370.
23. Guillem V.M., Cervantes F., Martínez J., Alvarez-Larrán A., Collado M., Camós M., et al. XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. Am J Hematol 2010, 85:482-486.
24. Vangsted A., Gimsing P., Klausen T.W., Nexø B.A., Wallin H., Andersen P., et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007, 120:1036-1045.
25. Neben K., Mytilineos J., Moehler T.M., Preiss A., Kraemer A., Ho A.D., et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002, 100:2263-2265.
26. Du J., Yuan Z., Zhang C., Fu W., Jiang H., Chen B., et al. Role of the TNF-alpha promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 2010, 34:1453-1458.
27. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999, 5:582-585.
28. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
29. Park D.J., Zhang W., Stoehlmacher J., Tsao-Wei D., Groshen S., Gil J., et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003, 1:162-166.
30. Hayden P.J., Tewari P., Morris D.W., Staines A., Crowley D., Nieters A., et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 2007, 16:3117-3127.
31. Tewari P., Kenny E., Staines A., Chanock S., Browne P., Lawler M. Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide. Blood 2009, 113:5691-5692.
32. Thompson M.A., Witzig T.E., Kumar S., Timm M.M., Haug J., Fonseca R., et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003, 123:305-308.
33. Vangsted A.J., Klausen T.W., Gimsing P., Andersen N.F., Abildgaard N., Gregersen H., et al. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 2009, 94:1274-1281.
34. Rosiñol L., Cibeira M.T., Segarra M., Cid M.C., Filella X., Aymerich M., et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004, 26:145-148.
35. Cavo M., Tacchetti P., Patriarca F., Petrucci M.T., Pantani L., Galli M., et al. A phase III study of double autotransplantation incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood 2009, 114:351. [abstract 351].
36. Rosiñol L., Cibeira M.T., Martinez J., Mateos M.V., Oriol A., Terol M.J., et al. Thalidomide/Dexamethasone (TD) Vs. Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. Blood 2009, 114:130. [abstract 130].
37. Attal M., Cristini C., Marit G., Caillot D., Facon T., Hullin C., et al. Intergroupe Francophone du Myelome. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol 2010, 28:8018. [abstract 8018].
38. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006, 36:825-831.
39. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
40. Palumbo A., Falco P., Corradini P., Falcone A., Di Raimondo F., Giuliani N., et al. GIMEMA-Italian Multiple Myeloma Network, Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4459-4465.
41. Lacy M.Q., Gertz M.A., Dispenzieri A., Hayman S.R., Geyer S., Kabat B., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007, 82:1179-1184.